Coronaviruses are a group of single-stranded RNA (positive) viruses [Figure 1] belonging to the subfamily Coronavirinae (Coronaviridae family). Based on genomic sequencing the subfamily Coronavirinae is further subdivided into four genera — Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus.[1] Over the last 20 years, betacoronavirus genera have produced two epidemics SARS CoV (2002-03), MERS CoV (2014-16).[2] An acute respiratory illness broke out in Wuhan, China in December 2019. A novel virus belonging to the genera betacoronavirus found to be causing this disease Corona Virus Disease-2019 (COVID-19) is presently classified as severe acute respiratory syndrome CoV 2 (SARS-CoV-2) virus. On February 1, 2020, WHO declared COVID-19 as a public health emergency of international concern. On the day of writing this editorial (04/04/2020), SARS-CoV-2 has infected 1,083,211 patients worldwide and 3,108 patients were infected in India. The case fatality rate of SARS CoV is 14-15%, MERS CoV is 35% and the rate of SARS- CoV-2 is around 2.5% suggesting that SARS- CoV-2 is less deadly than its cousins as on date.[3]

The incubation period of SARS-CoV-2 ranges from 1-14 days (mean incubation period: 5-6 days). SARS- CoV-2 spreads via air-borne droplet particles/aerosols (coughing and sneezing) or direct contact with the secretions of the infected individual producing human to human transmission. The droplet particles do not travel beyond 2 meters and do not remain in the air. Thus far, there is no evidence of intrauterine transmission or transmission during delivery.[2,4,5] SARS- CoV-2 has been extracted from stool samples however faeco-oral transmission has not been documented.[6] Basic reproduction number (R0) indicates the ability of an organism to spread. R0 of SARS-CoV-2 is 2-2.5. The serial interval (SI) is the time taken for successive cases to be infected. The mean serial interval for SARS- CoV-2 is 3.96 days (4-7 days) which much lower than 8.4 days documented for SARS CoV.[6,7] Majority of infections (approximately 81%) are mildly symptomatic, although these patients can spread the disease. R0, SI and large number of mildly symptomatic patients are epidemiologically significant and responsible for the exponential spread of the virus.

The natural reservoir of SARS CoV, MERS CoV is presumed to be bat and the intermediate hosts of SARS CoV and MERS CoV are palm civet and dromedary camel respectively. Early genomic matching studies suggest that the natural reservoir for SARS- CoV-2 is presumed to be bat and Malayan pangolin species extensively used in China for medicinal purposes are also involved in the transmission chain.[8,9]

The receptor for entry of SARS- CoV-2 is human angiotensin converting enzyme 2 (hACE 2) receptor present in respiratory epithelium and type II pulmonary pneumocyte which is the same as that of SARS CoV whereas MERS CoV utilizes the dipeptidyl peptidase 4 (DPP4) receptor for binding and entry.[10] The hACE 2 receptors are also expressed in the heart (cardiac myocytes, endothelium of myocardial vessels), kidney (proximal tubule, distal tubule) and major blood vessels (endothelium and smooth muscle cells). In the brain, the above receptors are seen in endothelium and smooth muscle cells of blood vessels. Animal studies (rat) have shown that the receptors are also seen in neurons.[10] Speculation that ACE inhibitors/Angiotensin receptor blockers upregulates ACE 2 receptor and increases the susceptibility to infection lacks evidence. It is advised that patients continue the ACE inhibitors/Angiotensin receptor blockers medications [Figure 2].[11]

SARS- CoV-2 replicates both in the upper and lower respiratory tract. This is in contrast with SARS CoV, as the latter has an affinity to the lower respiratory tract than the upper respiratory tract. The presence and multiplication of the virus in the upper respiratory tract is the reason for high infectivity than other viruses belonging to the group.[5]

81% of the infected patients are mildly symptomatic, 14% are severely symptomatic and 5% are critically ill. The most common manifestations of the infection include fever (92.8%), cough (69.8%), difficulty in breathing (34.5%), myalgia (27.7%), headache (7.2%), and diarrhoea (6.1%). The severity and complications of the disease are significantly higher in the elderly population. Age-dependent changes in the functions of T- and B- lymphocytes lead to excessive production of type 2 cytokines resulting in prolonged inflammatory response and cytokine storm that might explain the severity in the elderly. Severe manifestations of the respiratory system include pneumonia, ARDS. Other manifestations include sepsis, acute kidney injury, arrhythmia, acute cardiac injury, coagulopathy, and shock.[5,12]

Neurological manifestations are more likely in those with severe infections.[13] The neurological manifestations may be secondary to systemic effects of the virus or directly mediated by the virus. The altered sensorium that occurs in the infection may due to hypoxia, metabolic derangements or multi-organ dysfunction. The direct viral-mediated effects, as evidenced by the presence of SARS-CoV-2 in the cerebrospinal fluid, are probably mediated through hACE2 receptors. The viral access to the CNS may be facilitated hematogenously (probably infected macrophages acting as Trojan horses) or contiguous spread through the cribriform plate.[14] These manifestations include anosmia, dysgeusia, cerebral infarct, Intracerebral hemorrhage, aseptic meningitis, seizures, acute necrotizing encephalopathy. seizure and ataxia. It may also involve the
peripheral nervous system causing Guillain Barre syndrome and muscle injury.[13,15-19] The respiratory failure may also result from virus-mediated destruction of medullary neurons.[20] These manifestations described are far from complete as our understanding of the neurotropism and neurovirulence of the virus is likely to unfurl as the pandemic progresses [Figure 3].

Laboratory findings of SARS-CoV-2 infection include normal total blood count with lymphopenia which is the most consistent finding (reduced immunological response to the virus), reduced albumin (impaired liver function) with elevated liver enzymes and bilirubin (liver injury), elevated creatine (kidney injury), elevated lactate dehydrogenase (severe lung injury/multisystem involvement), elevated cardiac troponin (cardiac injury), elevated levels of D- dimer, prothrombin time and partial thromboplastin time and thrombocytopenia (consumption coagulopathy), elevated ferritin (severe viral infection) and elevated interleukin-6 (cytokine storm) and procalcitonin (secondary bacterial infection). Detection of viral nucleic acid from nasopharyngeal swab by real-time reverse transcriptase-polymerase chain reaction (RT-PCR), is now the GOLD STANDARD for confirming a suspected COVID-19 patient is now the GOLD STANDARD for confirming a suspected COVID-19 patient (sensitivity: 50-79%). The swab specimens are collected from the following sites: nasopharynx, oropharynx, expectorated sputum, lower respiratory tract aspirate, bronchoalveolar lavage and rectal swab. Rapid IgG/IgM antibody test has been developed, which can detect the presence of antibodies from blood,
serum or plasma (sensitivity: 85.6%, specificity: 91%)\[21\] and can serve as screening test for triage and epidemiological purposes [Figure 4]. Imaging modalities like chest X-ray shows ill defines opacities in lower zones of lung with the tendency to involve perihilar and upper lung fields in severe disease, CT chest reveals bilateral ground glass (air space) opacities in peripheral zone with predilection to involve lower zones and in some patients fine reticular opacities are also seen. USG lung revealed subpleural consolidation and B lines.\[22,23\]

Treatment options for COVID-19 include chloroquine/ hydroxychloroquine (inhibits virus entry into the cell by changing the glycosylation of hACE 2 receptor), remdesivir (RNA polymerase inhibitor), favipiravir (RNA polymerase inhibitor), lopinavir-ritonavir (protease inhibitors), tocilizumab (IL-6 receptor monoclonal antibody and preventing the effects of cytokine storm), ivermectin (inhibits the interaction between the viral integrase protein (IN) and the importin (IMP) α/β1 heterodimer responsible for IN nuclear import) and azithromycin (probable mechanism-inhibits mRNA expression and protein production, it is also immunomodulatory and decreases inflammatory response) [Figure 2].

Convalescent plasma from cured patients, Intravenous immunoglobulin has also been tried. The vaccine for COVID-19 is underway. Mechanical ventilation (invasive ventilation preferred over non-invasive ventilation) with low tidal volume and high PEEP setting, renal replacement therapy in acute kidney injury and other supportive treatment modalities are utilized in critically ill patients. The usage of corticosteroids in patients with severe ARDS is controversial and should be judiciously used.\[24-27\]

American heart association/American stroke association has proposed guidelines in the management of stroke patients during this pandemic insisting the judicious use of emergency services during this period, strictly following the suggested protocol.\[28\] National multiple sclerosis society also has made recommendations regarding the initiation/continuation/ modifications of disease modifying therapies in multiple sclerosis patients during the pandemic. Immunomodulators that do not increase the risk of infection include glatiramer acetate, interferons and natalizumab. Immunomodulators that increase the risk of infection include dimethyl fumarate, fingolimod, siponimod and teriflunomide. Immunosuppressants increasing the risk of infection include alemtuzumab, ocrelizumab, rituximab, mitoxantrone and cladribine.\[29\]

With the help, many novel methods like affinity purification-mass spectrometry, 29 viral proteins of SARS- CoV- 2 making 332 high confidence human protein-protein interactions are identified. These protein-protein interactome studies along with a combination of a systematic chemoinformatic drug search with a pathway centric analysis around 70 drugs that can be utilized to treat SARS-CoV- 2 have been identified and these compounds are now being tested for their efficacy against the virus.\[30\] This present pandemic since the Spanish flu of 1918 has seen rapid spread across geographies mainly due to extensive air travel and globalisation. It has also exposed the inadequacies of the global supply chain which has been largely a case of all eggs in one basket. Further, the rapid dissemination of information, true and otherwise, as seen an infodemic in the era of social media, which has resulted in unprecedented awareness of the disease in a short period of time. The downside has been the confusion and anxiety in the lay public caused by the torrent of information.

The absence of a specific curative drug and a vaccine has necessitated behavioural strategies to contain spread. The high infectivity and the presence of mildly symptomatic spreaders have resulted in an inability to quickly isolate infected patients. This has necessitated an unprecedented method of social distancing, a form of target population isolation with nearly one third of humanity under lockdown at the time of writing. However, the number of patients who acutely require intensive care in a short period of time has overwhelmed the capacity of intensive care systems around the world.

Containment strategies such as social distancing have been attempted to flatten the curve so as to stretch the epidemic over a larger period of time allowing for healthcare systems to cope with the patient load. Aggressive contact tracing and isolation in the earlier local transmission stage of the disease and surveillance once the epidemic has abated is required until the development of herd immunity or a vaccine.

Unprecedented fast tracking of vaccine development and strategies to develop mRNA vaccines as well as viral antigen preparations are in the pipeline. Since the description of the SARS CoV-2 genome in January 2020, vaccines like mRNA1273, a RNA printer a portable mRNA printing facility, INO -4800 a DNA Vaccine, monoclonal antibodies like sarilumab (IL-6 receptor antagonist), RNA interference oligonucleotides therapies (RNAi) like siRNA (small interfering RNA) and India based electroporated DNA vaccine are all in the race.\[31\]

The epidemiological behaviour of the virus remains to be observed including the possibility of seasonality and endemicity like influenza or a protracted spread over the medium term.

This will in turn necessitate population intervention strategies such as identification and containment of outbreaks and resumption of economic activities within the ambit of social distancing.

The pandemic shall entail medium to long term behavioural changes that will impact supply chains, economic models and sociocultural interactions.

Lakshmi Narasimhan  Ranganathan, Arun Shivaraman M. M, \[1\], Guhan Ramamurthy, R. Shrivarthan
Institute of Neurology, Madras Medical College, Chennai, Tamil Nadu, 1

Address for correspondence: Dr. Lakshmi Narasimhan Ranganathan, Institute of Neurology, Madras Medical College, Chennai, Tamil Nadu, India. E-mail: lakshmineuro@gmail.com

References

1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181-92.
2. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;202433. doi: 10.1016/j.jaut.2020.202433.
3. Lai CC, Shih TP, Ko WC, Tang HH, Hsuue PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924.
4. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). InStatPears [Internet] 2020 Mar 8. StatPears Publishing.
5. Heymann DL, Shindo N. COVID-19: What’s next for public health?. Lancet 2020;395:542-5.
6. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). [Last cited on 2020 Apr 09].
7. Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. The serial interval of COVID-19 from publicly reported confirmed cases. Emerg Infect Dis 2020;26:10.3201/eid2606.200357.
8. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol 2020. doi: 10.1016/j.cub.2020.03.022.
9. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020:1-3. doi: 10.1038/s41591-020-0820-9.
10. Xia H, Lazartigues E. Angiotensin-converting enzyme 2 in the brain: Properties and future directions. J Neurochem 2008;107:1482-94.
11. Patel AB, Verma A. COVID-19, and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence? JAMA 2020. doi: 10.1001/jama.2020.4812.
12. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Crit Infec Dis 2005;41(Suppl 7):S504-12.
13. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A retrospective case series study. 2020. doi: 10.2139/ssrn.3544840.
14. Baig AM, Khaaleq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS; Tissue distribution, host-virus interactions, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020;11:995-8.
15. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020. doi: 10.1016/j.bbi.2020.03.031.
16. Wang HY, Li XL, Yan ZR, Sun XP, Han J, Zhang BW. Potential neurological symptoms of COVID-19. Ther Adv Neurol Disord 2020;13:1756286420917830.
17. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neurol 2020. doi: 10.1016/S1474-4422(20)30109-5.
18. Poynard N, Shahnin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19 associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020;201187. doi: 10.1148/radiol.2020201187.
19. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. J Med Virol 2020. doi: 10.1002/jmv.25728.
20. Neurologic Symptoms and COVID-19: What’s Known, What Isn’t [Internet]. Available from: https://www.medscape.com/viewarticle/928157/vp_2. [Last cited on 2020 Apr 09].
21. Liu Y, Liu Y, Diao B, Ren F, Wang Y, Ding J, Huang Q. Diagnostic indexes of a rapid IgG/IgM combined antibody test for SARS-CoV-2. medRxiv. 2020. doi: 10.1101/2020.03.26.20044883.
22. Hosseiny M, Kooraki S, Gholamrezae nhad A, Reddy S, Myers L. Radiology perspective of coronavirus disease 2019 (COVID-19): Lessons from severe acute respiratory syndrome and Middle East respiratory syndrome. AJR Am J Roentgenol 2020:1-5. doi: 10.2214/AJR.20.22969.
23. Buonsenso D, Piano A, Raffaelli F, Bonadina N, Donati KD, Franceschi F. Novel coronavirus disease-19 pneumoniae: A case report and potential applications during COVID-19 outbreak. Eur Rev Med Pharmacol Sci 2020;24:2776-80.
24. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020. doi: 10.1001/jama.2020.4783.
25. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010;36:646-54.
26. Smith T, Bushek J, Prosser T. COVID-19 drug therapy. Clinical Drug Information, Clinical Solutions. Elsevier; 2020.
27. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Douidier B, et al. Hydroxychloroquine and azithromycin as a treatment for COVID-19 results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949. doi: 10.1016/j.ijantimicag.2020.105949.
28. Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic. Stroke [Internet]. Available from: https://doi.org/10.1161/STROKEAHA.120.030623. [Last cited on 2020 Apr 08].
29. Guidance for the use of disease modifying therapies during the COVID-19 pandemic. Available from: https://www.nationalmssociety.org/10.1161/STROKEAHA.120.030623. [Last cited on 2020 Apr 08].
30. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O’meara MJ, et al. SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. BioRxiv. 2020. doi: https:// doi.org/10.1101/2020.03.22.002386.
31. John Hodgson. The pandemic pipeline. Nat Biotechnol 2020. doi: 10.1038/d41587-020-00005-z.

Submitted: 06-Apr-2020 Accepted: 06-Apr-2020 Published: 10-Apr-2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: 10.4103/ain.AIAN_263_20

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.